Company news

Serina Therapeutics, Inc. news in 2025

Serina Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

December 11, 2025

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

December 10, 2025

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

November 13, 2025

Serina Therapeutics Provides Regulatory Update on SER-252 Program

November 3, 2025

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

October 8, 2025

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease

October 6, 2025

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease

September 9, 2025

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 8, 2025

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway

August 25, 2025

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

August 11, 2025

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

July 29, 2025

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

July 28, 2025

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

July 10, 2025

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

July 1, 2025

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

June 23, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

June 17, 2025

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

June 17, 2025

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 22, 2025

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 14, 2025

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 8, 2025

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

April 29, 2025

Decks in 2025